riluzole and Depressive Disorder, Major

riluzole has been researched along with Depressive Disorder, Major in 15 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (15)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Children's Yale-Brown Obsessive-Compulsive Scale Scores (CY-BOCS)

CY-BOCS is a 0-40 point scale of obsessive-compulsive symptom severity, higher number indicates more severe obsessive-compulsive symptoms. Comparison of 12 weeks scores for placebo and riluzole groups. (NCT00251303)
Timeframe: 12 weeks

Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I)

(NCT00251303)
Timeframe: 12 weeks

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

Clinical Global Impressions - Severity Scale (CGI-S)

The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

OCD Visual Analogue Scale (OCD-VAS)

"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Yale-Brown Obsessive Compulsive Challenge Scale (Y-BOCCS)

"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Change in Montgomery and Asberg Depression Rating Scale (MADRS)

"This 10 item instrument is completed by the clinician by using a structured interview and defined anchor points, and aims to quantify the degree of depression over the past 7 days. The MADRS is a widely studied instrument for depression, and its reliability and validity are high. This instrument is administered at every study visit during the double-blind RCT, and at the screening, and baseline. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression" (NCT01204918)
Timeframe: 4 weeks of therapy (baseline to week 4)

Change in Montgomery and Asberg Depression Rating Scale (MADRS)

"This 10 item instrument is completed by the clinician by using a structured interview and defined anchor points, and aims to quantify the degree of depression over the past 7 days. The MADRS is a widely studied instrument for depression, and its reliability and validity are high. This instrument is administered at every study visit during the double-blind RCT, and at the screening, and baseline. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression" (NCT01204918)
Timeframe: 4 weeks of therapy (week 4 to week 8)

Responders Having at Least a 50% Improvement in MADRS Compared to the Baseline

Responders having at least a 50% improvement in MADRS compared to the baseline in the sequential parallel design (NCT01204918)
Timeframe: 8 weeks therapy

Systematic Assessment for Treatment Emergent Events (SAFTEE-SI)

A commonly used instrument originally developed by NIMH and adapted into a self-report instrument. The version of the scale that we plan to use examines in a systematic fashion all possible treatment-emergent side effects and probes specific adverse symptoms, including suicidal thoughts and behaviors, and self-injurious behavior. Presented below are counts of people that had experienced the event by 8 weeks. (NCT01204918)
Timeframe: 8 weeks

Mean Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to the End of 8 Weeks of Therapy.

The Montgomery Asberg Depression Rating Scale measures symptoms of depression (MADRS) is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions with a fixed 7 point scale (0-6). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response will be defined as a > 50% reduction in MADRS score from baseline. (NCT00376220)
Timeframe: 8 weeks

VAS-anxiety Immediately After the Impromptu Speech Task

"Measure Description: In the Visual Analogue Scale (VAS) participants are presented with a straight horizontal line of 100 mm in length and asked to mark the placement that would best describe the intensity of the anxiety felt at that moment. The left end (0mm) represents no anxiety and the right end (100mm) represents the worst anxiety ever felt by the participant.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks, generating a numerical score along a continuum" (NCT03017508)
Timeframe: up to 60 minutes

Reviews

3 reviews available for riluzole and Depressive Disorder, Major

Trials

7 trials available for riluzole and Depressive Disorder, Major

Other Studies

5 other studies available for riluzole and Depressive Disorder, Major